Prostate Cancer
Conditions
Keywords
Prostate adenocarcinoma treated by radiotherapy
Brief summary
During the 7 to 8 weeks of conformal radiotherapy for prostate carcinoma, the prostate has an intra-pelvic motion which is not detectable by the conventional portal imaging. This prostate motion may lead to a mistargeting, which possibly decreases the local control. On the other hand, the new 3D on board imaging (3D OBI) allows to localize the target but is expensive. The cost/effectiveness ratio is not well established, as well as the frequency of using such imaging during the course of radiation.
Interventions
PROCEDUREControl position by 3DOBI before the fraction
PROCEDUREStandard imaging
Sponsors
National Cancer Institute, France
Gustave Roussy, Cancer Campus, Grand Paris
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
* prostate adenocarcinoma * intermediate / high risk group * N0 or N - * treatment by conformal radiotherapy (including or not IMRT), with or without androgen deprivation
Exclusion criteria
* pelvic irradiation * metal objects in the pelvis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prostate position under the LINAC is checked by 3D OBI (mainly cone-beam imaging, CBI) performed before the fraction. | — |
| To validate the optimal strategy of IGRT for prostate adenocarcinoma based on 2 and 5 year-disease free survival rates (events= biochemical failure or death). | — |
Secondary
| Measure | Time frame |
|---|---|
| Rectal and bladder, acute and late toxicities (CTCAE, SOMA-LENT) | — |
| Cost comparison and cost/effectiveness analysis | — |
| 2 and 5 years clinical relapse free survival rates | — |
| Lack of dose in the prostate in case of decreasing the CBI frequency (using the 1rst arm for testing) | — |
Countries
France
Outcome results
None listed